Collaboration and License Agreements - Fulcrum Therapeutics, Inc (Details) - Fulcrum Therapeutics, Inc. |
1 Months Ended | 3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|---|
|
Jul. 31, 2023
USD ($)
performanceObligation
|
Sep. 30, 2026
USD ($)
|
Sep. 30, 2025
USD ($)
|
Sep. 30, 2026
USD ($)
|
Sep. 30, 2025
USD ($)
|
Jun. 30, 2023
USD ($)
|
|
| Collaboration and License Agreements | ||||||
| Deferred revenue | $ 400,000 | |||||
| Variable consideration amount | $ 0 | $ 0 | ||||
| Number of performance obligations | performanceObligation | 1 | |||||
| Fixed consideration amount | $ 400,000 | |||||
| Research and collaboration revenue | $ 0 | $ 0 | $ 0 | $ 600,000 | ||
| Maximum | ||||||
| Collaboration and License Agreements | ||||||
| Variable consideration amount | $ 20,000,000.0 | $ 600,000 | ||||
| X | ||||||||||
- Definition Revenue, Performance Obligation, Number Of Performance Obligations No definition available.
|
| X | ||||||||||
- Definition Revenue, Remaining Performance Obligation, Fixed Consideration Amount No definition available.
|
| X | ||||||||||
- Definition Revenue, Remaining Performance Obligation, Variable Consideration Amount No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|